JAMDA
Volume 11, Issue 1 , Pages 26-32 , January 2010

ACE-Inhibition and Physical Function: Results From the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) Study

  • Matteo Cesari, MD, PhD

      Affiliations

    • Centro per la Salute dell'Anziano–Area di Geriatria, Università Campus Bio-Medico, Rome, Italy
    • Fondazione “Alberto Sordi,” Università Campus Bio-Medico, Rome, Italy
    • Department of Aging and Geriatric Research, University of Florida, Institute on Aging, Gainesville, FL
    • Corresponding Author InformationAddress correspondence to Matteo Cesari, MD, PhD, Centro per la Salute dell'Anziano–Area di Geriatria, Università Campus Bio-Medico, Via Alvaro del Portillo 5, 00128 Rome, Italy.
    • ,
  • Claudio Pedone, MD, PhD, MPH

      Affiliations

    • Centro per la Salute dell'Anziano–Area di Geriatria, Università Campus Bio-Medico, Rome, Italy
    • Fondazione “Alberto Sordi,” Università Campus Bio-Medico, Rome, Italy
    • ,
  • Raffaele Antonelli Incalzi, MD, PhD

      Affiliations

    • Centro per la Salute dell'Anziano–Area di Geriatria, Università Campus Bio-Medico, Rome, Italy
    • Fondazione “Alberto Sordi,” Università Campus Bio-Medico, Rome, Italy
    • ,
  • Marco Pahor, MD

      Affiliations

    • Department of Aging and Geriatric Research, University of Florida, Institute on Aging, Gainesville, FL

References 

  1. Guralnik JM, Fried LP, Salive ME. Disability as a public health outcome in the aging population. Annu Rev Public Health. 1996;17:25–46
  2. Pahor M, Blair SN, Espeland M, et al. Effects of a physical activity intervention on measures of physical performance: Results of the lifestyle interventions and independence for Elders Pilot (LIFE-P) study. J Gerontol A Biol Sci Med Sci. 2006;61:1157–1165
  3. Carter CS, Onder G, Kritchevsky SB, Pahor M. Angiotensin-converting enzyme inhibition intervention in elderly persons: effects on body composition and physical performance. J Gerontol A Biol Sci Med Sci. 2005;60:1437–1446
  4. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–691
  5. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713–720
  6. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645–652
  7. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597–603
  8. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–153
  9. Coirault C, Langeron O, Lambert F, et al. Impaired skeletal muscle performance in the early stage of cardiac pressure overload in rabbits: beneficial effects of angiotensin-converting enzyme inhibition. J Pharmacol Exp Ther. 1999;291:70–75
  10. Coirault C, Hagege A, Chemla D, et al. Angiotensin-converting enzyme inhibitor therapy improves respiratory muscle strength in patients with heart failure. Chest. 2001;119:1755–1760
  11. Onder G, Penninx BW, Balkrishnan R, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: An observational study. Lancet. 2002;359:926–930
  12. Sumukadas D, Witham MD, Struthers AD, McMurdo ME. Effect of perindopril on physical function in elderly people with functional impairment: A randomized controlled trial. CMAJ. 2007;177:867–874
  13. Carter CS, Cesari M, Ambrosius WT, et al. Angiotensin-converting enzyme inhibition, body composition, and physical performance in aged rats. J Gerontol A Biol Sci Med Sci. 2004;59:416–423
  14. Sumukadas D, Struthers AD, McMurdo ME. Sarcopenia—a potential target for angiotensin-converting enzyme inhibition?. Gerontology. 2006;52:237–242
  15. Bauer JM, Kaiser MJ, Sieber CC. Sarcopenia in nursing home residents. J Am Med Dir Assoc. 2008;9:545–551
  16. Yeh SS, Lovitt S, Schuster MW. Pharmacological treatment of geriatric cachexia: Evidence and safety in perspective. J Am Med Dir Assoc. 2007;8:363–377
  17. Bahi L, Koulmann N, Sanchez H, et al. Does ACE inhibition enhance endurance performance and muscle energy metabolism in rats?. J Appl Physiol. 2004;96:59–64
  18. Gray SL, LaCroix AZ, Aragaki AK, et al. Angiotensin-converting enzyme inhibitor use and incident frailty in women aged 65 and older: Prospective findings from the Women's Health Initiative Observational Study. J Am Geriatr Soc. 2009;57:297–303
  19. Schellenbaum GD, Smith NL, Heckbert SR, et al. Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. J Am Geriatr Soc. 2005;53:1996–2000
  20. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–2345
  21. Hutcheon SD, Gillespie ND, Crombie IK, et al. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: A randomised double blind placebo controlled trial. Heart. 2002;88:373–377
  22. Zi M, Carmichael N, Lye M. The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther. 2003;17:133–139
  23. Cranney A. Is there a new role for angiotensin-converting-enzyme inhibitors in elderly patients?. CMAJ. 2007;177:891–892
  24. Cesari M, Kritchevsky SB, Atkinson HH, et al. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: Results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009;157:334.e1–334.e8
  25. Cesari M, Kritchevsky SB, Baumgartner RN, et al. Sarcopenia, obesity, and inflammation—results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin Nutr. 2005;82:428–434
  26. Pahor M, Franse LV, Deitcher SR, et al. Fosinopril versus amlodipine comparative treatments study: A randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation. 2002;105:457–461
  27. Gullestad L, Aukrust P, Ueland T, et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol. 1999;34:2061–2067
  28. Greenbaum R, Zucchelli P, Caspi A, et al. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br J Clin Pharmacol. 2000;49:23–31
  29. Piepho RW. Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000;57(Suppl 1):S3–S7
  30. Hansson L, Forslund T, Hoglund C, et al. Fosinopril versus enalapril in the treatment of hypertension: A double-blind study in 195 patients. J Cardiovasc Pharmacol. 1996;28:1–5
  31. Wagstaff AJ, Davis R, McTavish D. Fosinopril: A reappraisal of its pharmacology and therapeutic efficacy in essential hypertension. Drugs. 1996;51:777–791
  32. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450–1456
  33. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955–1964
  34. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials. Lancet. 2000;356:1949–1954
  35. Onder G, Penninx BW, Lapuerta P, et al. Change in physical performance over time in older women: The Women's Health and Aging Study. J Gerontol A Biol Sci Med Sci. 2002;57:M289–M293
  36. Cesari M, Penninx BW, Pahor M, et al. Inflammatory markers and physical performance in older persons: The InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59:242–248
  37. Guralnik JM, Ferrucci L, Pieper CF, et al. Lower extremity function and subsequent disability: Consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55:M221–M231
  38. Guralnik JM, Ferrucci L, Simonsick EM, et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332:556–561
  39. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: Results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med. 2006;166:659–666
  40. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation. 1992;86:431–438
  41. Burke GL, Arnold AM, Bild DE, et al. Factors associated with healthy aging: The cardiovascular health study. J Am Geriatr Soc. 2001;49:254–262
  42. Newman AB, Arnold AM, Naydeck BL, et al. “Successful aging”: Effect of subclinical cardiovascular disease. Arch Intern Med. 2003;163:2315–2322

 The TRAIN study was funded by the National Institutes of Health (NIH grant R01-HL68901). The TRAIN study was also (partially) supported by the University of Florida Claude D. Pepper Older Americans Independence Center (NIH grant 1P30-AG028740), Wake Forest University Claude D. Pepper Older Americans Independence Center (NIH grant 5P30-AG021332), and the Wake Forest University General Clinical Research Center (NIH grant M01-RR07122). Fosinopril was donated by Bristol-Myers Squibb (New York, NY).

PII: S1525-8610(09)00347-8

doi: 10.1016/j.jamda.2009.09.014

JAMDA
Volume 11, Issue 1 , Pages 26-32 , January 2010

Article Tools